Last updated on August 2019

Efficacy Safety and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

Brief description of study

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 2 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. This study will compare the effects of apremilast to placebo on psoriatic arthritis subjects in which the number of affected joints is limited (greater than 1 but less or equal to 4). About 330 patients worldwide will take part in this study.

Clinical Study Identifier: NCT03747939

Find a site near you

Start Over

CHU Brugmann

Brussels, Belgium
  Connect »

Hopital Erasme

Brussels, Belgium
  Connect »